1. No category

ASOCIACIÓN ESPAÑOLA
AEMI
MICRO-INMUNOTERAPIA
¡Nuevo Contαct!
Nuevo Contact n°15 - Otoño 2013
Referencias bibliográficas
Inmunomodulación y sinergia terapéutica
1.
2.
3.
4.
5.
6.
7.
8.
9.
http://www.luzsanante.com/espanol/ProblemasConCamposElectromagneticos.aspx
http://sebbm.es/archivos_tinymce/mayo2010_federicomayor.pdf
Miriam Ruiz Ballester. Las proteínas G, receptores acoplados y el Nobel
de química Journal of Feelsynapsis (JoF). ISSN: 2254-3651. 2013.(8): 8589. http://feelsynapsis.com/jof/008/files/jof8_hd.pdf
Townsend MJ, McKenzie AN. Unravelling the net ? cytokines and diseases. J Cell Sci. 2000 Oct;113 (Pt 20):3549-50. http://jcs.biologists.org/
cgi/pmidlookup?view=long&pmid=11017869
http://sociedad.elpais.com/sociedad/2012/10/16/actualidad/1350402665_260949.html
http://www.guardian.co.uk/science/2012/oct/09/nobel-prize-chemistry2012-live
Smith Sonneborn J. Alternative strategy for Alzheimer's disease: stress response triggers. Int J Alzheimers Dis. 2012;2012:684283. Epub 2012 May
10. http://www.ncbi.nlm.nih.gov/pmc/articles/pmid/22655213/
Romeo J, Warnberg J, Gómez-Martínez S, Díaz LE, Marcos A. Neuroimmunomodulation by nutrition in stress situations. Neuroimmunomodulation. 2008;15(3):165-9. Epub 2008 Sep 9.
Wagner IJ, Rombeau JL. Nutritional support of surgical patients with inflammatory bowel disease. Surg Clin North Am. 2011 Aug;91(4):787-803,
viii.
10. Bourre JM. Effects of nutrients (in food) on the structure and function
of the nervous system: update on dietary requirements for brain. Part 1:
micronutrients. J Nutr Health Aging. 2006 Sep-Oct;10(5):377-85.
11. Grimble RF. Nutritional modulation of immune function. Proc Nutr Soc.
2001 Aug;60(3):389-97.
12. Oschman JL. Can electrons act as antioxidants? A review and commentary. J Altern Complement Med. 2007 Nov;13(9):955-67.
13. Chevalier G, Sinatra ST, Oschman JL, Sokal K, Sokal P. Earthing: health
implications of reconnecting the human body to the Earth's surface electrons. J Environ Public Health. 2012;2012:291541. Epub 2012 Jan 12.
http://www.ncbi.nlm.nih.gov/pmc/articles/pmid/22291721/
14. Todd P. Space radiation health: a brief primer. Gravit Space Biol Bull. 2003
Jun;16(2):1-4.
15. Emoto M. Healing with water. J Altern Complement Med. 2004
Feb;10(1):19-21.
16. Montagnier L, Aïssa J, Lavallée C, Mbamy M, Varon J, Chenal H. Electromagnetic detection of HIV DNA in the blood of AIDS patients treated by
antiretroviral therapy. Interdiscip Sci. 2009 Dec;1(4):245-53. Epub 2009
Nov 14.
ANEXO A
2LC1 – CASCADAS DE INMUNOREGULACIÓN SECUENCIAL en patología TUMORAL
1.
Kang DH, Weaver MT, Park NJ, Smith B, McArdle T, Carpenter J. Significant impairment in immune recovery after cancer treatment. Nurs Res.
2009 Mar-Apr;58(2):105-14.
2. Shimamura H, Cumberland R, Hiroishi K, Watkins SC, Lotze MT, Baar
J. Murine dendritic cell-induced tumor apoptosis is partially mediated by
nitric oxide. J Immunother. 2002 May-Jun;25(3):226-34.
3. Zou GM, Tam YK. Cytokines in the generation and maturation of dendritic cells: recent advances. Eur Cytokine Netw. 2002 Apr-Jun;13(2):186-99.
4. Mantovani A, Sica A, Locati M. New vistas on macrophage differentiation and activation. Eur J Immunol. 2007;37(1):14–16. doi: 10.1002/
eji.200636910.
5. Mantovani A, Bottazzi B, Colotta F, Sozzani S, Ruco L.The origin and function of tumor-associated macrophages. Immunol Today. 1992;13(7):265–
270. doi: 10.1016/0167-5699(92)90008-U.
6. Duque Correa MA, Rojas López M. Activación alternativa del macrófago: La diversidad en las respuestas de una célula de la inmunidad innata
ante la complejidad de los eventos de su ambiente. Inmunología 2007;
26(2) 73-86.
7. Leek RD, Harris AL, Yin-Xu Z, Xiao Mei L, Teng Z, Yu L, Jun Hua Z.
Tumor-associated macrophages in breast cancer. J Mammary Gland Biol
Neoplasia. 2002 Apr;7(2):177-89.
8. Standiford TJ, Kuick R, Bhan U, Chen J, Newstead M, Keshamouni VG.
TGF-β-induced IRAK-M expression in tumor-associated macrophages
regulates lung tumor growth. Oncogene. 2011 Jan 31. [Epub ahead of
print]
9. Steinman RM, Hawiger D, Nussenzweig MC. Tolerogenic dendritic cells.
Annu Rev Immunol 2003; 21: 685–711.
10. Guiducci C, Vicari AP, Sangaletti S, Trinchieri G, Colombo MP. Redirecting in vivo elicited tumor infiltrating macrophages and dendritic cells towards tumor rejection. Cancer Res. 2005 Apr 15;65(8):3437-46.
11. Levy EM, Roberti MP, Mordoh J. Natural killer cells in human cancer:
from biological functions to clinical applications. J Biomed Biotechnol.
2011;2011:676198. Epub 2011 Apr 26.
12. Juelke K, Killig M, Thiel A, Dong J, Romagnani C. Education of hyporesponsive NK cells by cytokines. Eur J Immunol. 2009 Sep;39(9):2548-55.
13. Vosshenrich CA, Ranson T, Samson SI, Corcuff E, Colucci F, Rosmaraki
EE, Di Santo JP. Roles for common cytokine receptor gamma-chain-dependent cytokines in the generation, differentiation, and maturation of
NK cell precursors and peripheral NK cells in vivo. J Immunol. 2005 Feb
1;174(3):1213-21.
14. Terabe M, Ambrosino E, Takaku S, O’Konek JJ, Venzon D, Lonning S,
McPherson JM, Berzofsky JA. Synergistic enhancement of CD8+ T cellmediated tumor vaccine efficacy by an anti-transforming growth factorbeta monoclonal antibody. Clin Cancer Res. 2009 Nov 1;15(21):6560-9.
Epub 2009 Oct 27.
15. Geldhof AB, Van Ginderachter JA, Liu Y, Noël W, Raes G, De Baetselier P. Antagonistic effect of NK cells on alternatively activated monocytes: a contribution of NK cells to CTL generation. Blood. 2002 Dec
1;100(12):4049-58. Epub 2002 Jul 25.
16. Vosshenrich CA, Ranson T, Samson SI, Corcuff E, Colucci F, Rosmaraki
EE, Di Santo JP. Roles for common cytokine receptor gamma-chain-dependent cytokines in the generation, differentiation, and maturation of
NK cell precursors and peripheral NK cells in vivo. J Immunol. 2005 Feb
1;174(3):1213-21.
17. Terabe M, Ambrosino E, Takaku S, O’Konek JJ, Venzon D, Lonning S,
McPherson JM, Berzofsky JA. Synergistic enhancement of CD8+ T cellmediated tumor vaccine efficacy by an anti-transforming growth factorbeta monoclonal antibody. Clin Cancer Res. 2009 Nov 1;15(21):6560-9.
doi: 10.1158/1078-0432.CCR-09-1066. Epub 2009 Oct 27.
18. Geldhof AB, Van Ginderachter JA, Liu Y, Noël W, Raes G, De Baetselier P. Antagonistic effect of NK cells on alternatively activated monocytes: a contribution of NK cells to CTL generation. Blood. 2002 Dec
1;100(12):4049-58. Epub 2002 Jul 25.
19. Grimm EA. Human lymphokine-activated killer cells (LAK cells) as a
potential immunotherapeutic modality. Biochim Biophys Acta. 1986 Dec
17;865(3):267-79.
20. Kwak JY, Han MK, Choi KS, Park IH, Park SY, Sohn MH, Kim UH,
McGregor JR, Samlowski WE, Yim CY. Cytokines secreted by lymphokine-activated killer cells induce endogenous nitric oxide synthesis
and apoptosis in DLD-1 colon cancer cells. Cell Immunol. 2000 Aug
1;203(2):84-94.
21. Richards JM. Therapeutic uses of interleukin-2 and lymphokine-activated
killer (LAK) cells. Blood Rev. 1989 Jun;3(2):110-9.
22. Yashin DV, Sashchenko LP, Kabanova OD, Luk’yanovaa TI, Dukhanina
EA, Romanova EA, Gnuchev NV. The CD8+population of LAK cells can
lyse both HLA-positive and HLA-negative cancer cell lines. Dokl Biol Sci.
2009 May-Jun;426:296-7.
23. Richards JM. Therapeutic uses of interleukin-2 and lymphokine-activated
killer (LAK) cells. Blood Rev. 1989 Jun;3(2):110-9.
24. Billiau AD, Sefrioui H, Overbergh L, Rutgeerts O, Goebels J, Mathieu C,
Waer M. Transforming growth factor-beta inhibits lymphokine activated
killer cytotoxicity of bone marrow cells: implications for the graft-versusleukemia effect in irradiation allogeneic bone marrow chimeras. Transplantation. 2001 Jan 27;71(2):292-9.
25. Falk CS, Noessner E, Weiss EH, Schendel DJ. Retaliation against tumor
cells showing aberrant HLA expression using lymphokine activated killer-derived T cells. Cancer Res. 2002 Jan 15;62(2):480-7.
26. Huysentruyt LC, Seyfried TN. Perspectives on the mesenchymal origin of
metastatic cancer. Cancer Metastasis Rev. 2010 Dec;29(4):695-707.
27. Gotzmann J, Mikula M, Eger A, Schulte-Hermann R, Foisner R, Beug
H, Mikulits W. Molecular aspects of epithelial cell plasticity: implications
for local tumor invasion and metastasis. Mutat Res. 2004 Jan;566(1):9-20.
28. McConkey DJ, Choi W, Marquis L, Martin F, Williams MB, Shah J, Svatek
R, Das A, Adam L, Kamat A, Siefker-Radtke A, Dinney C. Role of epithelial-to-mesenchymal transition (EMT) in drug sensitivity and metastasis
in bladder cancer. Cancer Metastasis Rev. 2009 Dec;28(3-4):335-44.
29. Gos M, Miłoszewska J, Przybyszewska M. [Epithelial-mesenchymal transition in cancer progression]. Postepy Biochem. 2009;55(2):121-8.
30. Chow G, Tauler J, Mulshine JL. Cytokines and growth factors stimulate
hyaluronan production: role of hyaluronan in epithelial to mesenchymal-like transition in non-small cell lung cancer. J Biomed Biotechnol.
2010;2010:485468. Epub 2010 Jun 30.
31. Reiman JM, Knutson KL, Radisky DC. Immune promotion of epithelialmesenchymal transition and generation of breast cancer stem cells. Cancer Res. 2010 Apr 15;70(8):3005-8.
32. Reiman JM, Knutson KL, Radisky DC. Immune promotion of epithelialmesenchymal transition and generation of breast cancer stem cells. Cancer Res. 2010 Apr 15;70(8):3005-8.
33. Yasuda H. Solid tumor physiology and hypoxia-induced chemo/radioresistance: novel strategy for cancer therapy: nitric oxide donor as a therapeutic enhancer. Nitric Oxide. 2008 Sep;19(2):205-16. Epub 2008 May 6.
34. Dachs GU and Stratford IJ (1996) The molecular response of mammalian
cells to hypoxia and the potential for exploitation in cancer therapy. Br J
Cancer 74: (Suppl XXVII) S126–S13.
35. Dachs GU and Tozer GM (2000) Hypoxia modulated gene expression:
angiogenesis, metastasis and therapeutic exploitation. Eur J Cancer 36:
1649–1660
36. De Ridder M, Verellen D, Verovski V, Storme G. Hypoxic tumor cell radiosensitization through nitric oxide. Cancer Res. 1998 Dec 15;58(24):56468.
37. Baritaki S, Huerta-Yepez S, Sahakyan A, Karagiannides I, Bakirtzi K,
Jazirehi A, Bonavida B. Mechanisms of nitric oxide-mediated inhibition of
EMT in cancer: inhibition of the metastasis-inducer Snail and induction
of the metastasis-suppressor RKIP. Cell Cycle. 2010 Dec 15;9(24):493140. Epub 2010 Dec 15.
38. Mitchell JB, Wink DA, DeGraff W, Gamson J, Keefer LK, Krishna MC.
Hypoxic mammalian cell radiosensitization by nitric oxide. Cancer Res.
1993;53:5845–5848
39. Verovski VN, Van den Berge DL, Soete GA, Bols BL, Storme GA. Intrinsic
radiosensitivity of human pancreatic tumour cells and the radiosensitising potency of the nitric oxide donor sodium nitroprusside. Br J Cancer.
1996;74:1734–1742
40. Janssens MY, Van den Berge DL, Verovski VN, Monsaert C, Storme
GA. Activation of inducible nitric oxide synthase results in nitric oxidemediated radiosensitization of hypoxic EMT-6 tumor cells. Cancer Res.
1998;58:5646–5648.
41. Huang J, Tatsumi T, Pizzoferrato E, Vujanovic N, Storkus WJ. Nitric oxide
sensitizes tumor cells to dendritic cell-mediated apoptosis, uptake, and
cross-presentation. Cancer Res. 2005 Sep 15;65(18):8461-70.
Anexo B
Bisfenol A – un importante perturbador del equilibrio hormonal humano
1.
Report of Joint FAO/WHO Expert Meeting to Review Toxicological and
Health Aspects of Bisphenol A (2010) (http://whqlibdoc.who.int/publications/2011/97892141564274_eng.pdf.)
2. Rubin BS., Bisphenol A: An endocrine disruptor with widespread exposure and multiple effects, J Steroid Biochem Mol Biol. 2011 May 13.
3. Weber Lozada K, Keri RA. Bisphenol A increases mammary cancer
risk in two distinct mouse models of breast cancer. Biol Reprod. 2011
Sep;85(3):490-7. doi: 10.1095/biolreprod.110.090431. Epub 2011 Jun 2.
4. Wetherill YB, Petre CE, Monk KR, Puga A, Knudsen KE. The xenoestrogen bisphenol A induces inappropriate androgen receptor activation and
mitogenesis in prostatic adenocarcinoma cells. Mol Cancer Ther. 2002
May;1(7):515-24.
5. Hess-Wilson JK. Bisphenol A may reduce the efficacy of androgen
deprivation therapy in prostate cancer. Cancer Causes Control. 2009
Sep;20(7):1029-37. doi: 10.1007/s10552-009-9337-8. Epub 2009 Apr 17.
6. Kim JY, Han EH, Kim HG, Oh KN, Kim SK, Lee KY, Jeong HG. Bisphenol
A-induced aromatase activation is mediated by cyclooxygenase-2 up-regulation in rat testicular Leydig cells. Toxicol Lett. 2010 Mar 15;193(2):2008. doi: 10.1016/j.toxlet.2010.01.011. Epub 2010 Jan 22.
7. Castro B, Sánchez P, Torres JM, Preda O, del Moral RG, Ortega E. Bisphenol A exposure during adulthood alters expression of aromatase and
5α-reductase isozymes in rat prostate. PLoS One. 2013;8(2):e55905. doi:
10.1371/journal.pone.0055905. Epub 2013 Feb 6.
8. Kim EJ, Lee D, Chung BC, Pyo H, Lee J. Association between urinary
levels of bisphenol-A and estrogen metabolism in Korean adults. Sci Total
Environ. 2013 Aug 15. pii: S0048-9697(13)00808-5. doi: 10.1016/j.scitotenv.2013.07.040. [Epub ahead of print]
9. Hengstler JG, Foth H, Gebel T, Kramer PJ, Lilienblum W, Schweinfurth
H, Völkel W, Wollin KM, Gundert-Remy U. Critical evaluation of key
evidence on the human health hazards of exposure to bisphenol A. Crit
Rev Toxicol. 2011 Apr;41(4):263-91. doi: 10.3109/10408444.2011.558487.
10. King CD, Rios GR, Green MD, Tephly TR. UDP-glucuronosyltransferases. Curr Drug Metab. 2000 Sep;1(2):143-61.
11. Inoue H, Tsuruta A, Kudo S, Ishii T, Fukushima Y, Iwano H, Yokota H,
Kato S. Bisphenol a glucuronidation and excretion in liver of pregnant
and nonpregnant female rats. Drug Metab Dispos. 2005 Jan;33(1):55-9.
Epub 2004 Oct 4.
12. Han SY, Huh CS, Ahn YT, Lim KS, Baek YJ, Kim DH. Hepatoprotective
effect of lactic acid bacteria, inhibitors of beta-glucuronidase production
against intestinal microflora. Arch Pharm Res. 2005 Mar;28(3):325-9.
13. Ginsberg G, Rice DC. Does rapid metabolism ensure negligible risk from
bisphenol A? Environ Health Perspect. 2009 Nov;117(11):1639-43. doi:
10.1289/ehp.0901010. Epub 2009 Jul 14.
14. Pearson JP, Pretlow TP, Bradley EL Jr, McGinnis MC, Pretlow TG. Betaglucuronidase activity in prostatic carcinoma and benign prostatic hyperplasia. Cancer. 1989 Aug 15;64(4):911-5.
15. WHITAKER BL. Plasma beta-glucuronidase levels in breast cancer. Br J
Cancer. 1960 Sep;14:471-7.
16. Cao K, Devanesan PD, Ramanathan R, Gross ML, Rogan EG, Cavalieri
EL. Covalent binding of catechol estrogens to glutathione catalyzed by
horseradish peroxidase, lactoperoxidase, or rat liver microsomes. Chem
Res Toxicol. 1998 Aug;11(8):917-24.
17. Gorlewska-Roberts KM, Teitel CH, Lay JO Jr, Roberts DW, Kadlubar FF.
Lactoperoxidase-catalyzed activation of carcinogenic aromatic and heterocyclic amines. Chem Res Toxicol. 2004 Dec;17(12):1659-66.
18. Cavalieri E, Rogan E. Catechol quinones of estrogens in the initiation of
breast, prostate, and other human cancers: keynote lecture. Ann N Y Acad
Sci. 2006 Nov;1089:286-301.
19. Gaikwad NW. Metabolomic profiling unravels DNA adducts in human
breast that are formed from peroxidase mediated activation of estrogens
to quinone methides. PLoS One. 2013 Jun 6;8(6):e65826. doi: 10.1371/
journal.pone.0065826. Print 2013.
20. Seifried HE, Anderson DE, Fisher EI, Milner JA. A review of the interaction among dietary antioxidants and reactive oxygen species. J. Nutr.
Biochem. 2007;18:567-579.
21. Deutsch JC. Ascorbic acid oxidation by hydrogen peroxide. Anal Biochem. 1998 Jan 1;255(1):1-7.
22. Sram RJ, Binkova B, Rossner P Jr. Vitamin C for DNA damage prevention. Mutat Res. 2012 May 1;733(1-2):39-49. doi: 10.1016/j.mrfmmm.2011.12.001. Epub 2011 Dec 13.
23. Ahn J, Gammon MD, Santella RM, Gaudet MM, Britton JA, Teitelbaum
SL, Terry MB, Nowell S, Davis W, Garza C, Neugut AI, Ambrosone CB.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
38.
39.
40.
41.
42.
43.
Associations between breast cancer risk and the catalase genotype, fruit
and vegetable consumption, and supplement use. Am J Epidemiol. 2005
Nov 15;162(10):943-52. Epub 2005 Sep 28.
Ketterer B, Meyer DJ. Glutathione transferases: a possible role in the detoxication and repair of DNA and lipid hydroperoxides. Mutat Res. 1989
Sep;214(1):33-40.
Glorieux C, Dejeans N, Sid B, Beck R, Calderon PB, Verrax J. Catalase
overexpression in mammary cancer cells leads to a less aggressive phenotype and an altered response to chemotherapy. Biochem Pharmacol.
2011 Nov 15;82(10):1384-90. doi: 10.1016/j.bcp.2011.06.007. Epub 2011
Jun 13.
Sipe HJ Jr, Jordan SJ, Hanna PM, Mason RP. The metabolism of 17 betaestradiol by lactoperoxidase: a possible source of oxidative stress in breast
cancer. Carcinogenesis. 1994 Nov;15(11):2637-43.
Neumann CM, Zannoni VG.Ascorbic acid deficiency and hepatic UDPglucuronyl transferase. Qualitative and quantitative differences. Biochem
Pharmacol. 1990 Mar 15;39(6):1085-93.
Suzuki E, Iwasaki R, Goto J, Matsuki Y, Nambara T. Synthesis of N-acetylcysteine conjugates of catechol estrogens. Steroids. 1996 May;61(5):296301.
Levy G. Sulfate conjugation in drug metabolism: role of inorganic sulfate.
Fed Proc. 1986 Jul;45(8):2235-40.
Coughtrie MW, Bamforth KJ, Sharp S, Jones AL, Borthwick EB, Barker
EV, Roberts RC, Hume R, Burchell A. Sulfation of endogenous compounds and xenobiotics--interactions and function in health and disease.
Chem Biol Interact. 1994 Jun;92(1-3):247-56.
Zhang Y, Callaway EC. High cellular accumulation of sulphoraphane, a
dietary anticarcinogen, is followed by rapid transporter-mediated export
as a glutathione conjugate. Biochem J. 2002 May 15;364(Pt 1):301-7.
Ho E, Beaver LM, Williams DE, Dashwood RH. Dietary factors and
epigenetic regulation for prostate cancer prevention. Adv Nutr. 2011
Nov;2(6):497-510. doi: 10.3945/an.111.001032. Epub 2011 Nov 3.
Cos S, González A, Martínez-Campa C, Mediavilla MD, Alonso-González
C, Sánchez-Barceló EJ. Melatonin as a selective estrogen enzyme modulator. Curr Cancer Drug Targets. 2008 Dec;8(8):691-702.
Zółtaszek R, Hanausek M, Kiliańska ZM, Walaszek Z. [The biological
role of D-glucaric acid and its derivatives: potential use in medicine].
Postepy Hig Med Dosw (Online). 2008 Sep 5;62:451-62.
Sisecioglu M, Cankaya M, Ozdemir H. Effects of some vitamins on lactoperoxidase enzyme activity. Int J Vitam Nutr Res. 2009 May;79(3):18894. doi: 10.1024/0300-9831.79.3.188.
Şişecioğlu M, Çankaya M, Gülçin İ, Özdemir H. Interactions of melatonin
and serotonin with lactoperoxidase enzyme. J Enzyme Inhib Med Chem.
2010 Dec;25(6):779-83. doi: 10.3109/14756360903425239. Epub 2010 Feb
2.
Yazdi MH, Mahdavi M, Kheradmand E, Shahverdi AR. The preventive
oral supplementation of a selenium nanoparticle-enriched probiotic increases the immune response and lifespan of 4T1 breast cancer bearing
mice. Arzneimittelforschung. 2012 Nov;62(11):525-31. doi: 10.1055/s0032-1323700. Epub 2012 Sep 3.
Yazdi MH, Mahdavi M, Setayesh N, Esfandyar M, Shahverdi AR. Selenium nanoparticle-enriched Lactobacillus brevis causes more efficient
immune responses in vivo and reduces the liver metastasis in metastatic form of mouse breast cancer. Daru. 2013 Apr 30;21(1):33. doi:
10.1186/2008-2231-21-33.
Knower KC, To SQ, Takagi K, Miki Y, Sasano H, Simpson ER, Clyne CD.
Melatonin suppresses aromatase expression and activity in breast cancer
associated fibroblasts. Breast Cancer Res Treat. 2012 Apr;132(2):765-71.
doi: 10.1007/s10549-012-1953-4. Epub 2012 Jan 12.
Cos S, González A, Martínez-Campa C, Mediavilla MD, Alonso-González
C, Sánchez-Barceló EJ. Melatonin as a selective estrogen enzyme modulator. Curr Cancer Drug Targets. 2008 Dec;8(8):691-702.
González A, Martínez-Campa C, Mediavilla MD, Alonso-González C,
Sánchez-Barceló EJ, Cos S. Inhibitory effects of pharmacological doses of
melatonin on aromatase activity and expression in rat glioma cells. Br J
Cancer. 2007 Sep 17;97(6):755-60. Epub 2007 Aug 14.
Tsuji M, Ito Y, Terada N, Mori H. Ovarian aromatase activity in scorbutic mutant rats unable to synthesize ascorbic acid. Acta Endocrinol (Copenh). 1989 Oct;121(4):595-602.
Tsuji M, Ito Y, Fukuda H, Terada N, Mori H. Aromatase activity and progesterone metabolism in ovaries of scorbutic mutant rats unable to synthesize ascorbic acid. Int J Vitam Nutr Res. 1989;59(4):353-9.
44. Milewich L, Chen GT, MacDonald PC, Peterson JA. Ascorbic acid inhibition of aromatase activity in human placenta tissue. J Steroid Biochem.
1981 Feb;14(2):185-93.
45. Cavalieri E, Rogan E. The molecular etiology and prevention of estrogen-initiated cancers. Mol Aspects Med. 2013 Aug 30. pii: S00982997(13)00060-5. doi: 10.1016/j.mam.2013.08.002.
46. Wu HJ, Liu C, Duan WX, Xu SC, He MD, Chen CH, Wang Y, Zhou Z, Yu
ZP, Zhang L, Chen Y. Melatonin ameliorates bisphenol A-induced DNA
damage in the germ cells of adult male rats. Mutat Res. 2013 Apr 15;752(12):57-67. doi: 10.1016/j.mrgentox.2013.01.005. Epub 2013 Feb 9.
47. Friso S, Choi SW. The potential cocarcinogenic effect of vitamin B12 deficiency. Clin Chem Lab Med. 2005;43(10):1158-63.
48. Ames BN. Micronutrients prevent cancer and delay aging. Toxicol Lett.
1998 Dec 28;102-103:5-18.
49. Nishizawa Y, Yamamoto T, Terada N, Fushiki S, Matsumoto K, Nishizawa
Y. Effects of methylcobalamin on the proliferation of androgen-sensitive
or estrogen-sensitive malignant cells in culture and in vivo. Int J Vitam
Nutr Res. 1997;67(3):164-70.
50. Yang D, Baumgartner RN, Slattery ML, Wang C, Giuliano AR, Murtaugh
MA, Risendal BC, Byers T, Baumgartner KB. Dietary intake of folate,
B-vitamins and methionine and breast cancer risk among Hispanic and
non-Hispanic white women. PLoS One. 2013;8(2):e54495. doi: 10.1371/
journal.pone.0054495. Epub 2013 Feb 11.
51. Wu W, Kang S, Zhang D. Association of vitamin B6, vitamin B12 and
methionine with risk of breast cancer: a dose-response meta-analysis. Br
J Cancer. 2013 Oct 1;109(7):1926-1944. doi: 10.1038/bjc.2013.438. Epub
2013 Aug 1.
52. Santos F, Wegkamp A, de Vos WM, Smid EJ, Hugenholtz J. High-Level
folate production in fermented foods by the B12 producer Lactobacillus
reuteri JCM1112. Appl Environ Microbiol. 2008 May;74(10):3291-4. doi:
10.1128/AEM.02719-07. Epub 2008 Mar 14.
53. Rossi M, Amaretti A, Raimondi S. Folate production by probiotic bacteria. Nutrients. 2011 Jan;3(1):118-34. doi: 10.3390/nu3010118. Epub 2011
Jan 18.
54. Stevens VL, McCullough ML, Sun J, Gapstur SM. Folate and other onecarbon metabolism-related nutrients and risk of postmenopausal breast
cancer in the Cancer Prevention Study II Nutrition Cohort. Am J Clin
Nutr. 2010 Jun;91(6):1708-15. doi: 10.3945/ajcn.2009.28553. Epub 2010
Apr 21.
55. Tomaszewski JJ, Richman EL, Sadetsky N, O'Keefe DS, Carroll PR, Davies
BJ, Chan JM. Impact of Folate Intake on Prostate Cancer Recurrence Following Definitive Therapy: Data from CaPSURE. J Urol. 2013 Oct 3. pii:
S0022-5347(13)05564-X. doi: 10.1016/j.juro.2013.09.065. [Epub ahead of
print]
56. de Vogel S, Meyer K, Fredriksen Å, Ulvik A, Ueland PM, Nygård O,
Vollset SE, Tell GS, Tretli S, Bjørge T. Serum folate and vitamin B12 concentrations in relation to prostate cancer risk--a Norwegian populationbased nested case-control study of 3000 cases and 3000 controls within
the JANUS cohort. Int J Epidemiol. 2013 Feb;42(1):201-10. doi: 10.1093/
ije/dys199.
57. Qin X, Cui Y, Shen L, Sun N, Zhang Y, Li J, Xu X, Wang B, Xu X, Huo
Y, Wang X. Folic acid supplementation and cancer risk: a meta-analysis
of randomized controlled trials. Int J Cancer. 2013 Sep 1;133(5):1033-41.
doi: 10.1002/ijc.28038. Epub 2013 Feb 15.
58. Lubecka-Pietruszewska K, Kaufman-Szymczyk A, Stefanska B, Fabianowska-Majewska K. Folic acid enforces DNA methylation-mediated
transcriptional silencing of PTEN, APC and RARbeta2 tumour suppressor genes in breast cancer. Biochem Biophys Res Commun. 2013 Jan
11;430(2):623-8. doi: 10.1016/j.bbrc.2012.11.103. Epub 2012 Dec 3.
59. Bistulfi G, Vandette E, Matsui S, Smiraglia DJ. Mild folate deficiency induces genetic and epigenetic instability and phenotype changes in prostate cancer cells. BMC Biol. 2010 Jan 21;8:6. doi: 10.1186/1741-7007-8-6.
60. Duthie SJ. Folate and cancer: how DNA damage, repair and methylation
impact on colon carcinogenesis. J Inherit Metab Dis. 2011 Feb;34(1):1019. doi: 10.1007/s10545-010-9128-0. Epub 2010 Jun 11.
61. Tisman G, Garcia A. Control of prostate cancer associated with withdrawal of a supplement containing folic acid, L-methyltetrahydrofolate
and vitamin B12: a case report. J Med Case Rep. 2011 Aug 25;5:413. doi:
10.1186/1752-1947-5-413.